{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:39:42Z","timestamp":1757623182479,"version":"3.44.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Psoriasis is associated with systemic inflammation and immune dysregulation, raising concerns about its potential link to antiphospholipid syndrome (APS). However, evidence on the risk of APS in psoriasis patients remains limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>This retrospective cohort study utilized data from the TriNetX US Collaborative Networks (2002\u20132022). Propensity score matching (1:1) was performed to balance demographic variables, comorbidities, and medication use between 288,678 psoriasis and non-psoriasis patients. The univariate Cox proportional hazard model and subgroup analyses were used to estimate the hazard ratio for APS. The Kaplan-Meier method was used to plot the cumulative incidence curves.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After matching, each cohort included 288,678 patients. Psoriasis patients exhibited significantly higher APS incidence (1,349 cases vs. 673 in controls; HR: 1.71, 95% CI: 1.56\u20131.88). Psoriatic arthritis (PsA) further amplified risk (HR: 1.91, 95% CI: 1.58\u20132.31). Subgroup analyses identified elevated APS susceptibility in older adults, females, Black\/African American individuals, and those with chronic comorbidities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Psoriasis and psoriatic arthritis are significant risk factors for APS, highlighting the need for targeted screening and management strategies in these populations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1620768","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:16:28Z","timestamp":1757391388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Increased risk of antiphospholipid syndrome in patients with psoriasis: a retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hsun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Ming","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14603","article-title":"Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta-analysis of randomized controlled trials","volume":"26","author":"Cai","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"19278","DOI":"10.1038\/s41598-023-43778-4","article-title":"Risk of incident autoimmune diseases in patients with newly diagnosed psoriatic disease: a nationwide population-based study","volume":"13","author":"Jung","year":"2023","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.hoc.2007.10.003","article-title":"Antiphospholipid antibody syndrome and autoimmune diseases","volume":"22","author":"Ostrowski","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.039","article-title":"The association of psoriasis with autoimmune diseases","volume":"67","author":"Wu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14750","article-title":"Absence of an association between gastrointestinal tract surgery and newly diagnosed psoriasis: A nationwide, population-based, nested, case-control study","volume":"26","author":"Liu","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.7.4733","article-title":"Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis","volume":"181","author":"Kryczek","year":"2008","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1189\/JLB.0109046","article-title":"IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines","volume":"86","author":"Ortega","year":"2009","journal-title":"J Leukoc Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","article-title":"Psoriasis","volume":"7","author":"Perera","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2687\u221297","DOI":"10.1002\/art.22802","article-title":"Anti\u2212beta2\u2212glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts","volume":"56","author":"Sorice","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.08.004","article-title":"Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome","volume":"48","author":"Noureldine","year":"2019","journal-title":"Semin Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1002\/art.39247","article-title":"Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome","volume":"67","author":"Yalavarthi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0038-1677040","article-title":"Neutrophil extracellular traps in arterial and venous thrombosis","volume":"45","author":"Laridan","year":"2019","journal-title":"Semin Thromb Hemost."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2010.08.012","article-title":"Neutrophils: Cinderella of innate immune system","volume":"10","author":"Kumar","year":"2010","journal-title":"Int Immunopharmacol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu397oa","article-title":"Activation of complement mediates antiphospholipid antibody-induced pregnancy loss","volume":"12","author":"Salmon","year":"2003","journal-title":"Lupus"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew040","article-title":"Complement activation is a crucial pathogenic factor in catastrophic antipho spholipid syndrome","volume":"55","author":"Barratt-Due","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the \u201cCAPS Registry","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2133.1986.tb02773.x","article-title":"Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses","volume":"114","author":"Takematsu","year":"1986","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-007-9074-0","article-title":"Angiogenesis and chronic inflammation: cause or consequence","volume":"10","author":"Costa","year":"2007","journal-title":"Angiogenesis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11926-018-0772-y","article-title":"Obstetric anti-phospholipid syndrome: state of the art","volume":"20","author":"Gerardi","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1077166","article-title":"Metabolic syndrome in antiphospholipid syndrome versus rheumatoid arthritis and diabetes mellitus: Association with arterial thrombosis, cardiovascular risk biomarkers, physical activity, and coronary atherosclerotic plaques","volume":"13","author":"Bolla","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102990","article-title":"Myocardial involvement in anti-phospholipid syndrome: Beyond acute myocardial infarction","volume":"21","author":"Coletto","year":"2022","journal-title":"Autoimmun Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1620768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:16:29Z","timestamp":1757391389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1620768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2025.1620768"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1620768","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"article-number":"1620768"}}